Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Meta-analysis suggests ibrutinib is safe, effective in DLBCL
Key clinical point: The pooled median progression-free and overall survival were 4.54 months and 11.5 months, respectively.
Major finding: The relapsed/refractory DLBCL achieved a pooled OR and CR of 49.7 % and 27.7 %, respectively.
Study details: Meta-analysis of 854 patients with DLBCL from 13 studies.
Disclosures: The study was supported by the Beijing Municipal Natural Science Foundation. The authors reported that they had no conflicts.
Citation:
Hou K et al. Critical Reviews in Oncology/Hematology. 2020; 152:doi.org/10.1016/j.critrevonc.2020.103010.